Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel

NCT04516928 | Completed

• 2 other identifiers: 2020-COVID19-292020-A02125-34
• Study Type: observational
• Target: 392
• Locations: 1 country
• Sites: 1

Brief Summary

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission is by droplet route, with an R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. During the period of containment, the majority of students from the Lyon-Bron Military Medical Schools were sent as reinforcement in Army Training Hospitals and in the Military Reanimation Unit (Mulhouse). Some students developed symptomatic forms of SARS-Cov-2 infection, documented by positive PCR, during Operation Resilience or on their return from the mission. The Lyon-Bron Military Medical Schools staff, exposed both to the initial phase of the epidemic and to national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus.

Conditions

SARS-CoV Infection; Covid19

Outcome Measures

Primary Outcomes (1)

• Proportion of anti-SARS-CoV2 seropositive participants

  The proportion of anti-SARS-CoV2 seropositive participants will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0.

  Day 0

Secondary Outcomes (4)

• Proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants)

  Day 0

• Correlation coefficient between medical risk factors and a positive serology

  Day 0

• Correlation coefficient between epidemiological risk factors and a positive serology

  Day 0

• Correlation coefficient between social risk factors and a positive serology

  Day 0

Interventions

Anti-SARS-CoV2 Serology DIAGNOSTIC_TEST

The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.

Questionnaire OTHER

A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will be composed of personnel of the Military Health Schools of Lyon-Bron (students, teachers, supervisors).

You may qualify if:

• at least 18 years of age
• personnel of the Military Health Schools of Lyon-Bron
• working at the Military Health Schools of Lyon-Bron during the COVID-19 crisis

You may not qualify if:

• under 18
• contraindication to blood sampling

Sponsors & Collaborators

• Direction Centrale du Service de Santé des Armées: lead

Study Sites (1)

Antenne Médicale des Ecoles Militaires de Santé de Lyon-Bron (EMSLB)

Bron, 69675, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples

MeSH Terms

Conditions

Severe Acute Respiratory Syndrome; COVID-19

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 14, 2020
• First Posted: August 18, 2020
• Study Start: September 21, 2020
• Primary Completion: September 25, 2020
• Study Completion: September 25, 2020
• Last Updated: March 9, 2021

Record last verified: 2021-03

Locations

FR (1)